We are live on ! Find out more
TARO

Taro Pharmaceutical Industries Ltd.

Delisted

TARO was delisted on the 21st of June, 2024.

101 hedge funds and large institutions have $318M invested in Taro Pharmaceutical Industries Ltd. in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 27

4% less funds holding

Funds holding: 105101 (-4)

9% less capital invested

Capital invested by funds: $351M → $318M (-$32.3M)

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
101
Holders Change
-4
Holders Change %
-3.81%
% of All Funds
2.21%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
12
Increased
36
Reduced
27
Closed
14
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
State of Tennessee, Department of Treasury
51
State of Tennessee, Department of Treasury
Tennessee
$424K
AIM
52
ARK Investment Management
Florida
$420K +$63.9K +787 +16%
LPL Financial
53
LPL Financial
California
$413K -$35.8K -441 -7%
Legal & General Group
54
Legal & General Group
United Kingdom
$409K
UBS Group
55
UBS Group
Switzerland
$361K -$633K -7,803 -62%
Janney Montgomery Scott
56
Janney Montgomery Scott
Pennsylvania
$340K
ARTA
57
A.R.T. Advisors
New York
$339K +$364K +4,490 New
Creative Planning
58
Creative Planning
Kansas
$329K
Deutsche Bank
59
Deutsche Bank
Germany
$328K -$18.1K -223 -5%
Vanguard Group
60
Vanguard Group
Pennsylvania
$313K -$487 -6 -0.1%
Two Sigma Advisers
61
Two Sigma Advisers
New York
$302K -$8.12K -100 -2%
State Street
62
State Street
Massachusetts
$289K
Barclays
63
Barclays
United Kingdom
$282K +$5.36K +66 +2%
Russell Investments Group
64
Russell Investments Group
United Kingdom
$268K -$3.57K -44 -1%
SFI
65
Susquehanna Fundamental Investments
Pennsylvania
$264K -$277K -3,410 -49%
KWMG
66
King Wealth Management Group
Florida
$264K +$284K +3,500 New
QI
67
QS Investors
New York
$263K +$89.3K +1,100 +46%
Squarepoint
68
Squarepoint
New York
$249K +$18K +222 +7%
New York State Common Retirement Fund
69
New York State Common Retirement Fund
New York
$210K
CSS
70
Cubist Systematic Strategies
Connecticut
$204K -$112K -1,385 -34%
QT
71
Quantbot Technologies
New York
$185K +$151K +1,865 +313%
PAM
72
Panagora Asset Management
Massachusetts
$112K
Mitsubishi UFJ Trust & Banking
73
Mitsubishi UFJ Trust & Banking
Japan
$98K +$106K +1,300 New
BlackRock
74
BlackRock
New York
$86K
QT
75
Quantamental Technologies
New York
$75K +$81.2K +1,000 New

TARO Hedge Fund Activity: Q3 2019 in Review

101 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q3 2019, worth a combined $318M — down 9.2% from $351M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of TARO and 12 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 36 added.

The largest buyer was Millennium Management, adding an estimated $4.48M. The largest seller was Strategic Global Advisors, exiting entirely with an estimated $6.27M sold.

  • 101 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q3 2019, down from 105 in Q2 2019.
  • Funds reported $318M of Taro Pharmaceutical Industries Ltd. stock for Q3 2019, down 9.2% quarter-over-quarter.
  • 12 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q3 2019 and 14 closed out, a net change of -2 holders.
  • The largest Taro Pharmaceutical Industries Ltd. buyer in Q3 2019 was Millennium Management, an estimated $4.48M added.
  • The largest Taro Pharmaceutical Industries Ltd. seller in Q3 2019 was Strategic Global Advisors, an estimated $6.27M sold.

Based on aggregated 13F filings for Q3 2019.